Androgens2016 Poster Presentations (1) (42 abstracts)
μ-Crystalline as hormone antagonist in prostate cancer
Olaf Merkel 1, , Osman Aksoy 1, , Martin Suzani 1, , Melanie Hassler 1, , Karin Schlangen 5 , Theresa Balber 6 , Markus Mitterhauser 6 , Ali Moazzami 7 , Michaela Schlederer 1 , Suzanne Turner 1, , Gerda Egger 1 , Gregor Hörmann 9 , Markus Hacker 6 , Zoran Culig 10 , Jan Pencik 1, & Lukas Kenner 1,
1Department of Clinical Pathology, Medical University Vienna, Vienna, Austria; 2Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria; 3Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, Vienna, Austria; 4Department of Urology, Medical University of Vienna, Vienna, Austria; 5Department of Biosimulation and Bioinformatics, Medical University Vienna, Vienna, Austria; 6Department of Nuclear Medicine, Medical University Vienna, Vienna, Austria; 7Department of Chemistry and Biotechnology, Swedish University of Agricultural Sciences, Uppsala, Uppsala, Sweden; 8Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK; 9Department of Laboratory Medicine, Medical University Vienna, Vienna, Austria; 10Department of Urology, Medical University Innsbruck, Innsbruck, Austria; 11Unit of Pathology of Laboratory Animals, University of Veterinary Medicine Vienna, Vienna, Austria. †These authors contributed equally.
Prostate cancer (PCa) is the most frequent cancer in men in the western world. PCa growth is highly dependent on androgens and androgen ablation is the cornerstone of current therapeutic approaches. μ-Crystalline (CRYM) is the main component of the kangaroohs eye’s lens. CRYM binds thyroid hormone (T3) in a NADPH dependent manner thereby sequestering it from being transcriptionally active in the nucleus. The role of CRYM in prostate cancer is largely unknown. This study identifies low CRYM as a negative prognostic factor in PCa using IHC and Kaplan-Meier analysis. In PCa CRYM expression was reduced, an effect that is further pronounced in metastases. In contrast, thyroid hormone receptor ß (TRβ) showed high expression in PCa that is again increased in metastases. Overexpression of CRYM in PCa cell lines led to increased uptake T3 and reduced invasive capacity. RNA sequencing transcriptome analysis of CRYM overexpressing PCa cell lines reveals androgen receptor and dihydrotestosteron induced genes to be highly specifically suppressed, identifying CRYM as a key hormone antagonist in PCa. Moreover, high CRYM expression leads to deregulated lipid metabolism. Finally, metabolome analysis using nuclear magnetic resonance (NMR) shows that high CRYM expression drastically reduces intracellular choline levels and is able to mask T3 effects in metastatic PC3 PCa cell line. Using PET/MRI we recently described choline levels as non-invasive biomarker for PCa surveillance. This study identifies CRYM as a prognostic factor and key antagonist to T3 and androgen signalling in PCa.
Presenting Author: Olaf Merkel, Department of Clinical Pathology, Medical University Vienna, Währinger Gürtel 18-20, 1090 Wien, Austria. Email: [email protected]
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more